Printer Friendly

Treatment is key to preventing ca in FAP patients.

SAN FRANCISCO -- Familial adenomatous polyposis, although relatively rare, is a major concern for individuals and families affected by the condition, Dr. Randall Burt said at a meeting on gastrointestinal cancers sponsored by the American Society of Clinical Oncology.

The disorder requires careful management, because untreated familial adenomatous polyposis (FAP) leads to colon cancer 100% of the time. Untreated patients develop colon cancer at an average age of 39 years, said Dr. Burt of the University of Utah in Salt Lake City.

He offered these tips for managing patients with FAP:

* Genetic testing is indicated in individuals and family members suspected of FAP. The disease should be suspected in any individual with more than 10-20 polyps. Available genetic tests have nearly 100% accuracy in detecting the autosomal dominant mutation that causes FAP.

* Genetic counseling is critical to help patients understand the illness and its consequences, and to deal with the psychological issues that may follow positive or negative tests. Patients need to understand the meaning of an indeterminate test, and they may need help dealing with economic and social issues. Some parents will want to have their young children tested, but Dr. Burt said that this testing should be discouraged until it becomes medically important, between the ages of 10 and 12 years.

* People with FAP develop hundreds or thousands of chronic adenomatous polyps, beginning at about age 16. Annual sigmoidoscopy should be performed starting between age 10 and 12 years for children who test positive for an FAP mutation. They should receive an upper endoscopy every 1-3 years, because patients with FAP often have gastric and duodenal adenomas that should be removed.

* Patients typically undergo a colectomy at the end of their high-school years. This greatly increases life expectancy.

* An attenuated form of FAP exists, in which patients typically develop only 10-30 polyps. The development of colon cancer is delayed about 10 years in these patients vs. patients who have the more common form of FAP, but their lifetime incidence is still 50%-80%. Colectomy is not always required for attenuated FAP.

* Congenital hypertrophy of the retinal pigment epithelium is a common comorbidity in patients with FAP, but Dr. Burt said this is never a clinical problem. Other common comorbidities are osteomas, epidermoid cysts, and fibromas, all generally of cosmetic interest only.

* Desmoid tumors may be more of a problem, especially in the abdomen. They are benign but can obstruct important structures such as the superior mesenteric artery, resulting in significant morbidity and even mortality. Desmoid tumors outside the abdomen are usually treated surgically. Treatment for those in the abdomen is delayed until they become symptomatic; chemotherapeutic approaches are typically used, but surgery and radiation may be necessary.

BY ROBERT FINN

San Francisco Bureau
COPYRIGHT 2004 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Genetic Testing Indicated; familial adenomatous polyposis
Author:Finn, Robert
Publication:Internal Medicine News
Geographic Code:1USA
Date:Mar 15, 2004
Words:454
Previous Article:Low-dose CT effectively identifies polyps.
Next Article:Aggressive treatment called best for barrett's esophagus.
Topics:


Related Articles
Genetic markers improve colorectal screen.
APC mutations in fecal DNA. (Clinical Capsules).
Cancer in familial polyposis. (Clinical Capsules).
Sulindac fails for FAP chemoprevention. (Familial Adenomatous Polyposis).
Hereditary Colon Cancer Association. (organizational spotlight).
Hereditary colon cancer.
Duodenal adenomatosis in FAP.
Managing genetic screening and risk in hereditary colon cancers.
Video capsule endoscopy misses many polyps in FAP.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters